4D Molecular Therapeutics FDMT Quick ratio
Quick ratio at other companies
Other financials
Where this comes from
Calculated from 4D Molecular Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's quick ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is 4D Molecular Therapeutics's quick ratio?
- 4D Molecular Therapeutics (FDMT) reported quick ratio of 9.3× in Q1 2026.
- How has 4D Molecular Therapeutics's quick ratio changed year-over-year?
- 4D Molecular Therapeutics's quick ratio decreased by 24.5% year-over-year, from 12.4× to 9.3×.
- What is the long-term trend for 4D Molecular Therapeutics's quick ratio?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's quick ratio has grown at a -11.1% compound annual growth rate (CAGR), from 16.9× to 9.4×.
- What does quick ratio mean?
- Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.